For the first time, a pharmaceutical company has acquired a drug candidate developed with resources from a National Institutes of Health (NIH) program for rare and neglected diseases (http://1.usa.gov/1kDK7XW).
The drug, called Aes-103, treats sickle cell disease by binding directly to hemoglobin and changing its structure, thereby reducing the sickling of red blood cells. It is the first drug specifically developed to target the underlying molecular mechanism of sickle cell disease.
Hampton T. Sickle Cell Drug Candidate Under Development. JAMA. 2014;312(8):779. doi:10.1001/jama.2014.10040
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.